In the last ASH annual meeting, the results of a phase I/II trial investigating the menin–MLL inhibitor DSP-5336 in R/R AML patients were presented; out of the six patients enrolled with R/R AML and KMT2A rearrangements, one patient achieved CRi, one patient achieved a morphologic leukemia-free state, and one achieved stable disease with the clearance of peripheral blasts, the recovery of peripheral counts, the resolution of leukemic gingival infiltration, and a reduction in bone marrow blasts from 85% to 31% [51]. Here, KMT2A is linked to leukemia.